利妥昔单抗治疗免疫性肾小球疾病50问
Fifty questions about the use of rituximab in the treatment of immune glomerular diseases
《利妥昔单抗治疗免疫性肾小球疾病50问》编写专家组 袁伟杰 1梅长林2
作者信息
- 1. 上海交通大学医学院附属第一人民医院肾脏科,上海200080
- 2. 海军军医大学附属长征医院肾脏病科,上海200003
- 折叠
摘要
利妥昔单抗(rituximab,RTX)是一种作用于B细胞表面CD20分子的人鼠嵌合单克隆抗体,目前在免疫性肾小球疾病治疗中的应用越来越广泛,然而基层临床医师在应用RTX过程中仍存在许多问题.鉴于此,我们就其中大家较为关注的50个临床问题,组织全国肾脏病专家进行了多轮的讨论修改编撰成本文.内容涵盖了 RTX治疗膜性肾病、微小病变肾病、抗中性粒细胞胞质抗体(antineutrophil cytoplasmic antibody,ANCA)相关性血管炎等免疫性肾小球疾病的适用范围、循证证据、治疗方案、药物使用方法及注意事项、特殊人群用药以及药物安全性等方面,尤其针对临床医师提出的典型问题进行了具体解答,旨在为广大临床医师提供实用的工作指导和参考.
Abstract
Rituximab(RTX)is a human mouse chimeric monoclonal antibody that acts on CD20 molecules on the surface of B cells.Currently,its application in the treatment of immune glomerular diseases is becoming increasingly widespread.However,there are still many problems in the application of RTX by clinical physicians.In response to this,we organized multiple rounds of discussions and revisions among national nephrologists on the 50 clinical issues that everyone is most concerned about and formed this article.The content covers the scope of application,evidence-based evidence,therapeutic regimen,drug usage methods and precautions,medication for special populations,and drug safety of rituximab in the treatment of membranous nephropathy,minimal change nephropathy,antineutrophil cytoplasmic antibody(ANCA)associated vasculitis and other immune glomerular diseases.In particular,specific answers are provided to typical questions raised by clinical doctors,aiming to provide practical guidance and reference for the broader clinicians.
关键词
肾小球肾炎,膜性/免疫抑制剂/抗中性粒细胞胞浆抗体相关性血管炎/利妥昔单抗Key words
Glomerulonephritis,membranous/Immunosuppressive agents/Anti-neutrophil cytoplasmic antibody-associated vasculitis/Rituximab引用本文复制引用
出版年
2024
NETL
NSTL
万方数据